State of Research in Ovarian Cancer Jonathan Ledermann
Boehringer Ingelheim’s Research Facility in Vienna and Ovarian Cancer Claudia-Nanette Gann
BIBF 1120 and angiogenesis inhibition Carlos Gil Ferreira
BIBF 1120 in ovarian cancer Keiichi Fujiwara
BIBF 1120* Mode of Action
Angiokinase inhibitors in lung cancer Marianne Nicolson
Personalised medicine and the future of oncology treatment Gerd Munzert
The latest data for BIBF 1120* in ovarian cancer Marianne Nicolson
Changing the outlook for personalised cancer therapy Boehringer Ingelheim
Targeted cancer therapies
Volasertib* and Polo-like kinase (Plk) inhibition
Angiokinase Inhibition and Nintedanib (BIBF 1120)*
BIBF 1120 anticancer agent
Mode of Action BIBF 1120* slide kit
BIBF 1120 (Vargatef) slide kit
Mutation detection with Quantitative Real Time PCR (Q-PCR)
Boehringer Ingelheim and the search for new targeted cancer treatments
Webcast South Korea, the evolution of lung cancer care
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.